Determination of the Membranous Expression of cMET in Patients with Advanced NSCLC and RET Fusions

RET fusions are found in 1-2% of patients (pts) with advanced non-small cell lung cancer (aNSCLC). RET inhibitors (RETi) are highly effective, but resistance eventually occurs. Antibody-drug conjugates (ADC) are promising treatments in aNSCLC, potentially employed at time of resistance, and cMET represents an emerging target in this setting. Specific data on cMET overexpression in RET+ aNSCLC are lacking.